Tumor and Microenvironment Evolution during Immunotherapy with Nivolumab

Cited by (1,002)

Items 401–500 of 1,002

1. Unleashing TNF cytotoxicity to enhance cancer immunotherapy
   Andrew J. Freeman, Conor J. Kearney, John Silke, Jane Oliaro · 2021 · Trends in Immunology
2. Comparative Analysis of Predictive Biomarkers for PD-1/PD-L1 Inhibitors in Cancers: Developments and Challenges
   Fang Yang, Jacqueline Wang, Yucai Wang, Baorui Liu, Julian R. Molina · 2021 · Cancers
3. Pharmaceutical targeting of OTUB2 sensitizes tumors to cytotoxic T cells via degradation of PD-L1
   Wenfeng Ren, Zilong Xu, Yating Chang, Fei Ju, Hongning Wu, Zhiqi Liang, Min Zhao, Naizhen Wang, Yanhua Lin, Chenhang Xu et al. · 2024 · Nature Communications
4. Navigating established and emerging biomarkers for immune checkpoint inhibitor therapy
   Stephen L. Wang, Timothy An-thy Chan · 2025 · Cancer Cell
5. Harnessing Tumor Evolution to Circumvent Resistance
   Katherine Lee McNamara, Christina N. Curtis · 2018 · Trends in Genetics
6. Reduced Neoantigen Expression Revealed by Longitudinal Multiomics as a Possible Immune Evasion Mechanism in Glioma
   Takahide Nejo, Hirokazu Matsushita, Takahiro Karasaki, Masashi Nomura, Kuniaki Saito, Shota Tanaka, Shunsaku Takayanagi, Taijun Hana, Satoshi Takahashi, Yosuke Kitagawa et al. · 2019 · Cancer Immunology Research
7. Tumor-targeted silencing of the peptide transporter TAP induces potent antitumor immunity
   Greta Garrido, Brett Schrand, Ailem Rabasa, Agata K. Levay, Francesca D’Eramo, Alexey Berezhnoy, Shrey Modi, Tal Gefen, Koen A. Marijt, Elien M. Doorduijn et al. · 2019 · Nature Communications
8. Single-cell transcriptomic analysis reveals gut microbiota-immunotherapy synergy through modulating tumor microenvironment
   Minyuan Cao, Yun Deng, Qing Hao, Huayun Yan, Q Wang, Chunyan Dong, Jing Wu, Yong He, Li‐Bin Huang, Xuyang Xia et al. · 2025 · Signal Transduction and Targeted Therapy
9. Approaches to Improve Chemically Defined Synthetic Peptide Vaccines
   Brett J. Hos, Elena Tondini, Sander I. van Kasteren, FERRY A. OSSENDORP · 2018 · Frontiers in Immunology
10. Integrated genomic analysis reveals mutated ELF3 as a potential gallbladder cancer vaccine candidate
    Akhilesh Pandey, Eric W. Stawiski, Steffen Durinck, Harsha Gowda, Leonard D. Goldstein, Mustafa Ahmed Barbhuiya, Markus Schröder, Sreelakshmi K. Sreenivasamurthy, Sun‐Whe Kim, Sameer Phalke et al. · 2020 · Nature Communications
11. Suppression of tumor antigen presentation during aneuploid tumor evolution contributes to immune evasion
    Reshmi Tripathi, Vishnu Modur, Laura Senovilla, Guido Kroemer, Kakajan Komurov · 2019 · OncoImmunology
12. The Role of PTEN Loss in Immune Escape, Melanoma Prognosis and Therapy Response
    Rita Cabrita, Shamik Mitra, Adriana Sanna, Henrik Ekedahl, Kristina Lövgren, Hakan Lars Olsson, Christian Ingvar, Karolin Isaksson, Martin Lauss, Ana Carneiro et al. · 2020 · Cancers
13. Genomic Landscape of Angiosarcoma: A Targeted and Immunotherapy Biomarker Analysis
    Andrea P. Espejo Freire, Andrew Elliott, Andrew Eric Rosenberg, Philippos Apolinário Costa, Priscila Barreto‐Coelho, Emily Jonczak, Gina Z. D’Amato, Ty K. Subhawong, Junaid Arshad, Julio Alexander Díaz-Pérez et al. · 2021 · Cancers
14. Using DNA sequencing data to quantify T cell fraction and therapy response
    Robert B. Bentham, Kevin Litchfield, Thomas B.K. Watkins, Emilia L. Lim, Rachel Rosenthal, Carlos Martínez‐Ruiz, Crispin T. Hiley, Maise Al Bakir, Roberto Salgado, David Allan Moore et al. · 2021 · Nature
15. IGF2BP family of RNA-binding proteins regulate innate and adaptive immune responses in cancer cells and tumor microenvironment
    Elcheva, Irina A., Gowda, Chethana P., Bogush, Daniel, Gornostaeva, Svetlana, Fakhardo, Anna, Sheth, Neil, Kokolus, Kathleen M., Sharma, Arati, Dovat, Sinisa, Uzun, Yasin et al. · 2023 · Frontiers in Immunology
16. Interleukin 17 signaling supports clinical benefit of dual CTLA-4 and PD-1 checkpoint inhibition in melanoma
    Renáta Váraljai, Lisa Zimmer, Yahya Saleh Al-Matary, Paulien Kaptein, Lea Jessica Albrecht, Batool Shannan, Jan C. Brase, Daniel Gusenleitner, Teresa Maria Santos Amaral, Nina Wyss et al. · 2023 · Nature Cancer
17. Neoadjuvant vidutolimod and nivolumab in high-risk resectable melanoma: A prospective phase II trial
    Diwakar Davar, Robert M. Morrison, Amiran Dzutsev, Arivarasan D. Karunamurthy, Joë-Marc Chauvin, Florent Amatore, Julie Stein Deutsch, Rodrigo Xavier das Neves, Richard Rosario Rodrigues, John A. McCulloch et al. · 2024 · Cancer Cell
18. Melanoma Immunotherapy: Next-Generation Biomarkers
    Sabrina A. Hogan, Mitchell Paul Levesque, Phil Fang Cheng · 2018 · Frontiers in Oncology
19. The new identified biomarkers determine sensitivity to immune check-point blockade therapies in melanoma
    Hao Chen, Meng Yang, Qinghua Wang, Fengju Song, Xiangchun Li, Kexin Chen · 2019 · OncoImmunology
20. Identification of gastric cancer subtypes based on pathway clustering
    Lin Li, Xiaosheng Wang · 2021 · npj Precision Oncology
21. Safety and effectiveness of neoadjuvant PD-1 inhibitor (toripalimab) plus chemotherapy in stage II–III NSCLC (LungMate 002): an open-label, single-arm, phase 2 trial
    Xinsheng Zhu, Liangdong Sun, Nan Song, Wenxin He, Boxiong Xie, Junjie Hu, Jing Zhang, Jie Yang, Jie Dai, Dongliang Bian et al. · 2022 · BMC Medicine
22. Positive Association Between Location of Melanoma, Ultraviolet Signature, Tumor Mutational Burden, and Response to Anti–PD-1 Therapy
    L. Dousset, F. Poizeau, Caroline Robert, Sandrine Mansard, Laurent Mortier, Charline Caumont, Émilie Routier, Alain Dupuy, Jacques Rouanet, Maxime Battistella et al. · 2021 · JCO Precision Oncology
23. Nivolumab plus ipilimumab in advanced salivary gland cancer: a phase 2 trial
    Joris L. Vos, Bharat Burman, Swati Jain, Conall W. R. Fitzgerald, Eric Jeffrey Sherman, Lara Ann Dunn, James Vincent Fetten, Loren Scott Michel, Anuja Kriplani, Kenneth Ng et al. · 2023 · Nature Medicine
24. Influence of Tumor Immune Infiltration on Immune Checkpoint Inhibitor Therapeutic Efficacy: A Computational Retrospective Study
    Rong Liu, Fang Yang, Ji‐Ye Yin, Yingzi Liu, Wei Zhang, Hong‐Hao Zhou · 2021 · Frontiers in Immunology
25. CD20+CD22+ADAM28+ B Cells in Tertiary Lymphoid Structures Promote Immunotherapy Response
    Zhenghao Wu, Junjie Zhou, Yunxiao Xiao, Jie Ming, Jing Zhou, Fang Dong, Xiaoqi Zhou, Zhuoshuo Xu, Xiangwang Zhao, Ping Lei et al. · 2022 · Frontiers in Immunology
26. Transcriptomic profiling reveals distinct subsets of immune checkpoint inhibitor induced myositis
    Iago Pinal‐Fernandez, Ángela Quintana, Jose César Milisenda, María Casal-Domínguez, Sandra Muñoz-Braceras, Assia Derfoul, Jiram José Torres-Ruiz, Katherine S. Pak, Stefania Dell’Orso, Faiza Naz et al. · 2023 · Annals of the Rheumatic Diseases
27. Current State of Melanoma Therapy and Next Steps: Battling Therapeutic Resistance
    Anna Fateeva, Kevinn Eddy, Suzie Chen · 2024 · Cancers
28. The Role of Molecular Profiling to Predict the Response to Immune Checkpoint Inhibitors in Lung Cancer
    Courèche Kaderbhaï, Zoé Tharin, François Ghiringhelli · 2019 · Cancers
29. Targeting Immune-Related Biological Processes in Solid Tumors: We do Need Biomarkers
    Fabio Pagni, Elena Guerini‐Rocco, Anne Maria Schultheis, Giulia Grazia, Erika Rijavec, Michele Ghidini, Gianluca Lopez, Konstantinos Venetis, Giorgio Alberto Croci, Umberto Malapelle et al. · 2019 · International Journal of Molecular Sciences
30. Characterization of neoantigen-specific T cells in cancer resistant to immune checkpoint therapies
    Shamin Li, Yannick Simoni, Summer Zhuang, Austin M. Gabel, Shaokang Ma, Jonathan Chee, Laura Islas, Anthony Cessna, Jenette Creaney, Robert K. Bradley et al. · 2021 · Proceedings of the National Academy of Sciences
31. Prediction of prognosis, immunogenicity and efficacy of immunotherapy based on glutamine metabolism in lung adenocarcinoma
    Jichang Liu, Hongchang Shen, Wenchao Gu, Haotian Zheng, Yadong Wang, Guoyuan Ma, Jiajun Du · 2022 · Frontiers in Immunology
32. PD-1 defines a distinct, functional, tissue-adapted state in Vδ1+ T cells with implications for cancer immunotherapy
    Daniel Davies, Shraddha Kamdar, Richard Woolf, Iva Zlatareva, Maria Luisa Iannitto, Cienne Morton, Yasmin Haque, Hannah Martin, Dhruva Biswas, Susan Ndagire et al. · 2024 · Nature Cancer
33. Emerging biomarkers for the combination of radiotherapy and immune checkpoint blockers
    Claire Lhuillier, Claire Vanpouille‐Box, Lorenzo Galluzzi, Silvia Chiara Formenti, Sandra Demaria · 2017 · Seminars in Cancer Biology
34. A Computational Model of Neoadjuvant PD-1 Inhibition in Non-Small Cell Lung Cancer
    Mohammad Jafarnejad, Chang Gong, Edward Gabrielson, Imke Heleen Bartelink, Paolo Vicini, Bing Wang, Rajesh Narwal, Lorin K. Roskos, Aleksander S. Popel · 2019 · The AAPS Journal
35. Preanalytic Variables and Tissue Stewardship for Reliable Next-Generation Sequencing (NGS) Clinical Analysis
    Paolo A. Ascierto, Carlo Bruno Bifulco, Giuseppe Palmieri, Solange Peters, Nikoletta Sidiropoulos · 2019 · Journal of Molecular Diagnostics
36. Immunological ignorance is an enabling feature of the oligo-clonal T cell response to melanoma neoantigens
    Gerald P. Linette, Michelle Becker‐Hapak, Zachary L. Skidmore, Miren Lorea Baroja, Chong Bing Xu, Jasreet Hundal, David H. Spencer, Weixuan Fu, Casey Cummins, Maya Robnett et al. · 2019 · Proceedings of the National Academy of Sciences
37. Transcriptomic datasets of cancer patients treated with immune-checkpoint inhibitors: a systematic review
    Szonja Kovacs, Balázs Győrffy · 2022 · Journal of Translational Medicine
38. Sarcoma microenvironment cell states and ecosystems are associated with prognosis and predict response to immunotherapy
    Ajay Subramanian, Neda Nemat‐Gorgani, Timothy John Ellis-Caleo, David G.P. van IJzendoorn, Timothy J. Sears, Anish Somani, Bogdan A. Luca, Maggie Yuxi Zhou, Martina Bradić, Ileana A. Torres et al. · 2024 · Nature Cancer
39. IGSF8 is an innate immune checkpoint and cancer immunotherapy target
    Yulong Li, Xiangyang Wu, Caibin Sheng, Hailing Liu, Huizhu Liu, Yixuan Tang, Chao Liu, Qingyang Ding, Bin Xie, Xi Xiao et al. · 2024 · Cell
40. Keeping Tumors in Check: A Mechanistic Review of Clinical Response and Resistance to Immune Checkpoint Blockade in Cancer
    Nicholas C. Borcherding, Ryan H. Kolb, Jodi A. Gullicksrud, Praveen Vikas, Yuwen Zhu, Weizhou Zhang · 2018 · Journal of Molecular Biology
41. Biomarkers for Immune Checkpoint Inhibitors in Melanoma
    Shigehisa Kitano, Takayuki Nakayama, Makiko Yamashita · 2018 · Frontiers in Oncology
42. Predicting clinical benefit of immunotherapy by antigenic or functional mutations affecting tumour immunogenicity
    Kwoneel Kim, Hong Sook Kim, Jeong Yeon Kim, Hyunchul Jung, Jong‐Mu Sun, Jin Seok Ahn, Myung‐Ju Ahn, Keunchil Park, Se‐Hoon Lee, Jung Kyoon Choi · 2020 · Nature Communications
43. Resistance to immunotherapy in human malignancies: Mechanisms, research progresses, challenges, and opportunities
    Davood Bashash, Zahra Zandi, Bahareh Kashani, Atieh Pourbagheri‐Sigaroodi, Sina Salari, Seyed Hamidollah Ghaffari · 2021 · Journal of Cellular Physiology
44. Antigen and checkpoint receptor engagement recalibrates T cell receptor signal strength
    Thomas A.E. Elliot, Emma K. Jennings, David A.J. Lecky, Natasha Thawait, Adriana Flores‐Langarica, Alastair Copland, Kendle M. Maslowski, David Cameron Wraith, David Bending · 2021 · Immunity
45. DENR controls JAK2 translation to induce PD-L1 expression for tumor immune evasion
    Baiwen Chen, Jiajia Hu, Xianting Hu, Huifang Chen, Rujuan Bao, Yatao Zhou, Youqiong Ye, Meixiao Zhan, Wei Cai, Huabin Li et al. · 2022 · Nature Communications
46. PRKDC : new biomarker and drug target for checkpoint blockade immunotherapy
    Kien Thiam Tan, Chun‐Nan Yeh, Yu‐Chan Chang, Jen-Hao Cheng, Wen‐Liang Fang, Yi‐Chen Yeh, Yu‐Chao Wang, Dennis Shin‐Shian Hsu, Chiao‐En Wu, Jiun‐I Lai et al. · 2020 · Journal for ImmunoTherapy of Cancer
47. New tools to prevent cancer growth and spread: a ‘Clever’ approach
    Maija Hollmén, Carlos R. Figueiredo, Sirpa Jalkanen · 2020 · British Journal of Cancer
48. Plasma-derived extracellular vesicle analysis and deconvolution enable prediction and tracking of melanoma checkpoint blockade outcome
    Alvin Shi, Gyulnara G. Kasumova, William A. Michaud, Jessica Cintolo-Gonzalez, Marta Díaz‐Martínez, Jacqueline F. Ohmura, Arnav Mehta, Isabel Chien, Dennie Tompers Frederick, Sonia Cohen et al. · 2020 · Science Advances
49. NKG7 Is Required for Optimal Antitumor T-cell Immunity
    Xian-Yang Li, Dillon Corvino, Bianca Nowlan, Amelia Roman Aguilera, Susanna S. Ng, Matthias Braun, Anthony Richard Cillo, Tobias Bald, Mark John Smyth, Christian R. Engwerda · 2022 · Cancer Immunology Research
50. Ubiquitin ligase STUB1 destabilizes IFNγ-receptor complex to suppress tumor IFNγ signaling
    Georgi Apriamashvili, David W. Vredevoogd, Oscar Krijgsman, Onno B. Bleijerveld, Maarten Alexander Ligtenberg, Beaunelle de Bruijn, Julia Boshuizen, Joleen J.H. Traets, Daniela M. D'Empaire Altimari, Alex v. Vliet et al. · 2022 · Nature Communications
51. Rewiring chaperone-mediated autophagy in cancer by a prion-like chemical inducer of proximity to counteract adaptive immune resistance
    Jin Yan, Dan Liu, Jingmei Wang, Weiming You, Wenguang Yang, Siqi Yan, Wangxiao He · 2023 · Drug Resistance Updates
52. Overcoming therapy resistance in pancreatic cancer: New insights and future directions
    Margarita Espona‐Fiedler, Cédric Patthey, Stina Lindblad, Irina Sarró, Daniel Öhlund · 2024 · Biochemical Pharmacology
53. CAR T Cell Therapy for Pediatric Brain Tumors
    John D. Patterson, Jeffrey Curran Henson, Rebecca O. Breese, Kevin Bielamowicz, Analiz Rodriguez · 2020 · Frontiers in Oncology
54. Deconvolving Clinically Relevant Cellular Immune Cross-talk from Bulk Gene Expression Using CODEFACS and LIRICS Stratifies Patients with Melanoma to Anti–PD-1 Therapy
    Kun Wang, Sushant Patkar, Joo Sang Lee, E. Michael Gertz, Welles Robinson, Fiorella Schischlik, David R. Crawford, Alejandro A. Schäffer, Eytan Ruppin · 2022 · Cancer Discovery
55. Modulating tumor physical microenvironment for fueling CAR-T cell therapy
    Zhong Yuan Luo, Xuemei Yao, Menghuan Li, De Fang, Yang Fei, Zhuo Cheng, Yingying Xu, Bo Zhu · 2022 · Advanced Drug Delivery Reviews
56. Germline modifiers of the tumor immune microenvironment implicate drivers of cancer risk and immunotherapy response
    Meghana S. Pagadala, Timothy J. Sears, Victoria H. Wu, Eva Pérez‐Guijarro, Hyo Kim, Andrea Castro, James V. Talwar, Cristian González-Colín, Steven Cao, Benjamin Joachim Schmiedel et al. · 2023 · Nature Communications
57. Inhibition of MAN2A1 Enhances the Immune Response to Anti–PD-L1 in Human Tumors
    Sailing Shi, Shengqing Stan Gu, Tong Han, Wubing Zhang, Lei Huang, Ziyi Li, Deng Pan, Jingxin Fu, Jun Ge, Myles A Brown et al. · 2020 · Clinical Cancer Research
58. An Empirical Antigen Selection Method Identifies Neoantigens That Either Elicit Broad Antitumor T-cell Responses or Drive Tumor Growth
    Hubert Lam, Lisa Kristin McNeil, Hanna Starobinets, Victoria L. DeVault, Roger B. Cohen, Przemyslaw W. Twardowski, Melissa Lynne Johnson, Maura L. Gillison, Mark N. Stein, Ulka N. Vaishampayan et al. · 2021 · Cancer Discovery
59. Neoantigen vaccine platforms in clinical development: understanding the future of personalized immunotherapy
    Suangson Supabphol, Lijin Li, Simon Peter Goedegebuure, William E. Gillanders · 2021 · Expert Opinion on Investigational Drugs
60. Deep learning reveals predictive sequence concepts within immune repertoires to immunotherapy
    Sidhom, John-William, Oliveira, Giacomo, Ross-MacDonald, Petra, Wind-Rotolo, Megan, Wu, Catherine J., Pardoll, Drew M., Baras, Alexander S. · 2022 · Science Advances
61. Lymph node and tumor-associated PD-L1+ macrophages antagonize dendritic cell vaccines by suppressing CD8+ T cells
    Jenny Sprooten, Isaure Vanmeerbeek, Angeliki Datsi, Jannes Govaerts, Stefan Naulaerts, Raquel Salvador Laureano, Daniel Borràs, Anna Calvet, Vanshika Malviya, Marc Kuballa et al. · 2024 · Cell Reports Medicine
62. ITPRIPL1 binds CD3ε to impede T cell activation and enable tumor immune evasion
    Shouyan Deng, Yibo Zhang, Huanbin Wang, Wenhua Liang, Lu Xie, Ning Li, Yuan Fang, Yiting Wang, Jiayang Liu, Hao Chi et al. · 2024 · Cell
63. A mutation-based gene set predicts survival benefit after immunotherapy across multiple cancers and reveals the immune response landscape
    Junyu Long, Dongxu Wang, Anqiang Wang, Peipei Chen, Yu Syuan Lin, Jin‐Song Bian, Xu Yang, Mingjun Zheng, Haohai Zhang, Yongchang Zheng et al. · 2022 · Genome Medicine
64. Pan-Cancer Analysis Reveals a Distinct Neutrophil Extracellular Trap-Associated Regulatory Pattern
    Xiaotian Shen, Sun‐Zhe Xie, Jing Xu, Luyu Yang, Lun–Xiu Qin · 2022 · Frontiers in Immunology
65. Community assessment of methods to deconvolve cellular composition from bulk gene expression
    Brian S. White, Aurélien de Reyniès, Aaron M. Newman, Joshua J. Waterfall, Andrew E. Lamb, Florent Petitprez, Yating Lin, Rongshan Yu, Martin E. Guerrero-Gimenez, Sergii Domanskyi et al. · 2024 · Nature Communications
66. Choosing tumor mutational burden wisely for immunotherapy: A hard road to explore
    Rui Li, Dongsheng Han, Jiping Shi, Yanxi Han, Ping Tan, Rui Zhang, Jinming Li · 2020 · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer
67. TCF1+PD-1+ tumour-infiltrating lymphocytes predict a favorable response and prolonged survival after immune checkpoint inhibitor therapy for non-small-cell lung cancer
    Jaemoon Koh, Sehui Kim, Yeon Duk Woo, Seung Geun Song, Jeemin Yim, Bogyeong Han, Sojung Lim, Hyun Kyung Ahn, Seungchan Mun, Jung Sun Kim et al. · 2022 · European Journal of Cancer
68. Multi-omics analysis uncovers tumor ecosystem dynamics during neoadjuvant toripalimab plus nab-paclitaxel and S-1 for esophageal squamous cell carcinoma: a single-center, open-label, single-arm phase 2 trial
    Guoqing Zhang, Jing Yuan, Chaohu Pan, Qing Xu, Xiaoli Cui, Jing Zhang, Minglu Liu, Zhigang Song, Liangliang Wu, Dongfang Wu et al. · 2023 · EBioMedicine
69. Breaking NGF–TrkA immunosuppression in melanoma sensitizes immunotherapy for durable memory T cell protection
    Tao Yin, Guoping Wang, Liuyang Wang, Poorva Mudgal, Ergang Wang, Christopher C. Pan, Peter B. Alexander, Haiyang Wu, Chengjie Cao, Yaosi Liang et al. · 2024 · Nature Immunology
70. Functional heterogeneity of lymphocytic patterns in primary melanoma dissected through single-cell multiplexing
    Francesca Maria Bosisio, Asier Antoranz, Yannick Van Herck, Maddalena M. Bolognesi, Lukas Marcelis, Clizia Chinello, Jasper Wouters, Fulvio Magni, Leonidas G. Alexopoulos, Marguerite Stas et al. · 2020 · eLife
71. Precision Medicine Approaches to Overcome Resistance to Therapy in Head and Neck Cancers
    Sandra Ortiz‐Cuaran, Jebrane Bouaoud, Andy Karabajakian, Jérôme Fayette, Pierre Saintigny · 2021 · Frontiers in Oncology
72. Neoadjuvant programmed death-1 blockade plus chemotherapy in locally advanced esophageal squamous cell carcinoma
    Guozhen Yang, Xiaodong Su, Hong Yang, Guangyu Luo, Chan Gao, Yating Zheng, Wenzhuan Xie, Mengli Huang, Ting Bei, Yuezong Bai et al. · 2021 · Annals of Translational Medicine
73. Lymph node macrophages drive immune tolerance and resistance to cancer therapy by induction of the immune-regulatory cytokine IL-33
    Sara Lamorte, Rene Quevedo, Robbie Jin, Luke A. Neufeld, Zhe Qi Liu, M. Teresa Ciudad, Sabelo Lukhele, Jessica K. Bruce, Shreya V. Mishra, Xin Zhang et al. · 2025 · Cancer Cell
74. Ultraviolet light and melanoma
    Sarah Craig, Charles H. Earnshaw, Amaya Virós · 2018 · The Journal of Pathology
75. Bioinformatic Methods and Bridging of Assay Results for Reliable Tumor Mutational Burden Assessment in Non-Small-Cell Lung Cancer
    Chang Han, Ariella Sasson, Sujaya Srinivasan, Ryan Golhar, Danielle M. Greenawalt, William J. Geese, George Alexander Green, Kim E. Zerba, Stefan A. Kirov, Joseph D. Szustakowski · 2019 · Molecular Diagnosis & Therapy
76. The Evolving Landscape of Biomarkers for Anti-PD-1 or Anti-PD-L1 Therapy
    Antje Tunger, Ulrich J. Sommer, Rebekka Wehner, Anne Sophie Kubasch, Marc‐Oliver Grimm, Michael Philipp Bachmann, Uwe Platzbecker, Martin Bornhäuser, Gustavo Bruno Baretton, Marc Schmitz · 2019 · Journal of Clinical Medicine
77. Enhancing KDM5A and TLR activity improves the response to immune checkpoint blockade
    Liangliang Wang, Yan Gao, Gao Zhang, Dan Li, Zhenda Wang, Jie Zhang, Leandro C. Hermida, Lei He, Zhisong Wang, Jingwen Si et al. · 2020 · Science Translational Medicine
78. Conserved Interferon-γ Signaling Drives Clinical Response to Immune Checkpoint Blockade Therapy in Melanoma
    Catherine S. Grasso, Jennifer Tsoi, Mykola I. Onyshchenko, Gabriel Abril-Rodríguez, Petra Ross‐Macdonald, Megan Wind‐Rotolo, Ameya S. Champhekar, Egmidio Medina, Davis Yuri Torrejon, Daniel Sanghoon Shin et al. · 2020 · Cancer Cell
79. An interim report on the investigator-initiated phase 2 study of pembrolizumab immunological response evaluation (INSPIRE)
    Derek Clouthier, Scott C. Lien, S.Y. Cindy Yang, Linh T. Nguyen, Venkata SK. Manem, Diana Gray, Michael C. Ryczko, Albiruni R. Abdul Razak, Jeremy Howard Lewin, Stéphanie Lheureux et al. · 2019 · Journal for ImmunoTherapy of Cancer
80. Widespread hypertranscription in aggressive human cancers
    Matthew Zatzman, Fabio Fuligni, Ryan Ripsman, Tannu Suwal, Federico Comitani, Lisa-Monique Edward, Robert Edward Denroche, Gun Ho Jang, Faiyaz Notta, Steve Gallinger et al. · 2022 · Science Advances
81. IL-27 elicits a cytotoxic CD8+ T cell program to enforce tumour control
    Béatrice Bréart, Katherine Williams, Stellanie Krimm, Tiffany Wong, Brandon D. Kayser, Lifen Wang, Eric Cheng, Mayra Cruz Tleugabulova, Romain Bouziat, Tianshi Lu et al. · 2025 · Nature
82. LAG3 (CD223) and autoimmunity: Emerging evidence
    Suiyuan Hu, Xu Liu, Tianding Li, Zhanguo Li, Fanlei Hu · 2020 · Journal of Autoimmunity
83. Tumor-infiltrating TNFRSF9 + CD8 + T cells define different subsets of clear cell renal cell carcinoma with prognosis and immunotherapeutic response
    Yaohui Li, Zewei Wang, Wenbin Jiang, Han Zeng, Zhaopei Liu, Zhiyuan Lin, Yang Qu, Ying Xiong, Jiajun Wang, Yuan Chang et al. · 2020 · OncoImmunology
84. T‐cell exhaustion interrelates with immune cytolytic activity to shape the inflamed tumor microenvironment
    Mei‐Chun Cai, Xiaojing Zhao, Min Cao, Pengfei Ma, Minjiang Chen, Jie Wu, Chenqiang Jia, Chunming He, Yujie Fu, Li Tan et al. · 2020 · The Journal of Pathology
85. Replication Stress Defines Distinct Molecular Subtypes Across Cancers
    Nobuyuki Takahashi, Se Hyun Kim, Christopher William Schultz, Vinodh N. Rajapakse, Yang Zhang, Christophe E. Redon, Haiqing Fu, Lőrinc Sándor Pongor, Suresh Kumar, Yves G. Pommier et al. · 2021 · Cancer Research Communications
86. Navigating the immune landscape with plasma cells: A pan‐cancer signature for precision immunotherapy
    Bicheng Ye, Aimin Jiang, Liang Feng, Changcheng Wang, Xiaoqing Liang, Pengpeng Zhang · 2024 · BioFactors
87. Acquired resistance to cancer immunotherapy
    Arianna Draghi, Christopher Aled Chamberlain, Andrew J.S. Furness, Marco Donia · 2018 · Seminars in Immunopathology
88. Prognostic Value of Neutrophil–Lymphocyte Ratio, Platelet–Lymphocyte Ratio, and Combined Neutrophil–Lymphocyte Ratio and Platelet–Lymphocyte Ratio in Stage IV Advanced Gastric Cancer
    Huan Wang, Yongfeng Ding, Ning Li, Luntao Wu, Yuan Gao, Xiao Cheng, Haiping Jiang, Yulong Zheng, Chenyu Mao, Jing Deng et al. · 2020 · Frontiers in Oncology
89. Obesity and the Impact on Cutaneous Melanoma: Friend or Foe?
    Lorey K. Smith, Shaghayegh Arabi, Emily J. Lelliott, Grant A. McArthur, Karen E. Sheppard · 2020 · Cancers
90. A novel scoring method based on RNA‐Seq immunograms describing individual cancer‐immunity interactions
    Yukari Kobayashi, Yoshihiro Kushihara, Noriyuki Saito, Shigeo Yamaguchi, Kazuhiro Kakimi · 2020 · Cancer Science
91. Paired whole exome and transcriptome analyses for the Immunogenomic changes during concurrent chemoradiotherapy in esophageal squamous cell carcinoma
    Sehhoon Park, Je‐Gun Joung, Yang Won Min, Jae‐Yong Nam, Daeun Ryu, Dongryul Oh, Woong‐Yang Park, Se Kyung Lee, Yoon‐La Choi, Jin Seok Ahn et al. · 2019 · Journal for ImmunoTherapy of Cancer
92. Succinate preserves CD8+ T cell fitness to augment antitumor immunity
    Kaili Ma, Hongcheng Cheng, Lin Wang, Han Xiao, Fenghua Liu, Yu Ting Yang, Zhen Xiao, Kun Tang, Shicheng Li, Gang Wang et al. · 2025 · Immunity
93. CD4+ T cells induce rejection of urothelial tumors after immune checkpoint blockade
    Yuji Sato, Jennifer K. Bolzenius, Abdallah M. Eteleeb, Xinming Su, Christopher A. Maher, Jennifer K. Sehn, Vivek K. Arora · 2018 · JCI Insight
94. Comprehensive Outline of Whole Exome Sequencing Data Analysis Tools Available in Clinical Oncology
    Áron Bartha, Balázs Győrffy · 2019 · Cancers
95. Tumor-Derived IL33 Promotes Tissue-Resident CD8+ T Cells and Is Required for Checkpoint Blockade Tumor Immunotherapy
    Lujun Chen, Runzi Sun, Junchi Xu, Wensi Zhai, Dachuan Zhang, Min Yang, Cuihua Yue, Yichao Chen, Song Li, Heth Roderick Turnquist et al. · 2020 · Cancer Immunology Research
96. SOX2 promotes resistance of melanoma with PD-L1 high expression to T-cell-mediated cytotoxicity that can be reversed by SAHA
    Ruiyan Wu, Caiqin Wang, Zhiming Li, Jian Xiao, Chunyan Li, Xuemin Wang, Pengfei Kong, Jianghua Cao, Fuxue Huang, Zhi‐Ling Li et al. · 2020 · Journal for ImmunoTherapy of Cancer
97. Precision Medicine and Melanoma: Multi-Omics Approaches to Monitoring the Immunotherapy Response
    Fabio Valenti, Italia Falcone, Sara Ungania, Flora Desiderio, Patrizio Giacomini, Chiara Bazzichetto, Fabiana Conciatori, Enzo Gallo, Francesco Cognetti, Gennaro Ciliberto et al. · 2021 · International Journal of Molecular Sciences
98. Immune Cell Profiling of Peripheral Blood as Signature for Response During Checkpoint Inhibition Across Cancer Types
    Vinicius Araújo Barbosa de Lima, Morten Hansen, Iben Spanggaard, Kristoffer Staal Rohrberg, Sine Reker Hadrup, Ulrik Lassen, Inge Marie Svane · 2021 · Frontiers in Oncology
99. Temporally restricted activation of IFNβ signaling underlies response to immune checkpoint therapy in mice
    Rachael M. Zemek, Wee Loong Chin, Vanessa S. Fear, Ben Wylie, Thomas H. Casey, Cath Forbes, Caitlin M. Tilsed, Louis Boon, Belinda B. Guo, Anthony Bosco et al. · 2022 · Nature Communications
100. Enhancer decommissioning by MLL4 ablation elicits dsRNA-interferon signaling and GSDMD-mediated pyroptosis to potentiate anti-tumor immunity
     Hanhan Ning, SHAN HU HUANG, Lei Yang, Renyong Zhi, Han Yan, Jiaxing Jin, Zhenyu Hu, Kaimin Guo, Jinhua Liu, Jie Yang et al. · 2022 · Nature Communications